TransMedics Group saw an improvement in its IBD SmartSelect Composite Rating Tuesday, from 92 to 96.
Lean How — And When — To Sell Stocks
The upgrade means the stock is now outpacing 96% of all other stocks in terms of key performance metrics and technical strength. History shows the top market performers tend to have a 95 or higher score as they launch their major climbs.
TransMedics Group is currently forming a consolidation, with a 145.50 entry. See if the stock can break out in volume at least 40% above average.
The stock sports an 81 EPS Rating, meaning its recent quarterly and longer-term annual earnings growth tops 81% of all stocks.
Its Accumulation/Distribution Rating of A shows heavy buying by institutional investors, such as mutual funds and pension funds, over the last 13 weeks.
The company reported 163% EPS growth for Q2. It has now posted accelerating EPS growth for two consecutive quarters. Sales growth came in at 38%, down from 48% in the previous quarter.
TransMedics Group earns the No. 2 rank among its peers in the Medical-Products industry group. Insulet is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
